Testosterone

Generic Name: Testosterone

Brand Names: Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₈O_₂

CAS Number: 58-22-0

Unique Ingredient Identifier: 3XMK78S47O

Background: Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism. Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.

Testosterone was isolated from samples and also synthesized in 1935.

Indication: Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.

Associated Conditions: Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism, Idiopathic Hypogonadotropic Hypogonadism, Puberty, Delayed, Inoperable, metastatic Breast cancer

Associated Therapies: -

Clinical Trials

Insulin Sensitivity in Men With the Metabolic Syndrome

Not Applicable

Suspended

Conditions: Metabolic Syndrome

Interventions: Procedure: intravenous glucose tolerance test
Procedure: aerobic capacity (VO2 Max)
Drug: testosterone
Procedure: MRI
Drug: goserelin acetate implant
Drug: anastrozole
Procedure: muscle biopsy
Procedure: measurement of resting metabolic rate (energy expenditure)
Procedure: Dual energy x-ray absorptiometry
Procedure: Fasting oral glucose tolerance test

First Posted Date: 2007-02-09

Last Posted Date: 2010-03-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 72

Registration Number: NCT00433173

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen

Phase 3

Completed

Conditions: Hypoactive Sexual Desire Disorder

Interventions: Drug: Placebo
Drug: Testosterone

First Posted Date: 2006-10-04

Last Posted Date: 2013-04-17

Lead Sponsor: Warner Chilcott

Target Recruit Count: 272

Registration Number: NCT00384046

Locations: 🇬🇧
Research Facility, Warks, United Kingdom
🇬🇧
Site Facility, Headington, Oxford, United Kingdom

Testosterone Effects on Men With the Metabolic Syndrome

Phase 2

Withdrawn

Conditions: Metabolic Syndrome

First Posted Date: 2006-09-28

Last Posted Date: 2008-12-05

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Target Recruit Count: 72

Registration Number: NCT00382057

Pharmacokinetics of Testosterone Lotion in the Treatment of Hypogonadal Males

Phase 2

Completed

Conditions: Hypogonadism

First Posted Date: 2006-09-06

Last Posted Date: 2008-06-20

Lead Sponsor: Acrux DDS Pty Ltd

Target Recruit Count: 40

Registration Number: NCT00372008

Locations: 🇺🇸
Birmingham, Birmingham, Alabama, United States

Testosterone Replacement in Diabetes With Vascular Disease (Version 2)

Phase 4

Completed

Conditions: Diabetes Mellitus
Peripheral Vascular Disease

Interventions: Drug: 0.9% saline
Drug: Testosterone

First Posted Date: 2006-07-24

Last Posted Date: 2010-03-30

Lead Sponsor: Barnsley Hospital

Target Recruit Count: 19

Registration Number: NCT00355537

Locations: 🇬🇧
Barnsley Hospital NHS Foundation Trust, Barnsley, South Yorkshire, United Kingdom

Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception

Phase 2

Completed

Conditions: Pain
Hypogonadism

Interventions: Drug: AndroGel
Other: Placebo

First Posted Date: 2006-07-13

Last Posted Date: 2017-06-28

Lead Sponsor: Boston University

Target Recruit Count: 84

Registration Number: NCT00351819

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism

Phase 4

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: androgel 10g
Drug: placebo
Drug: androgel

First Posted Date: 2006-07-11

Last Posted Date: 2022-02-10

Lead Sponsor: University at Buffalo

Target Recruit Count: 49

Registration Number: NCT00350701

Locations: 🇺🇸
Diabetes-Endocrinology Center of Western NY, 115 flint road, Buffalo, New York, United States

Testosterone for Men With Insulin Treated Type 2 Diabetes

Phase 4

Completed

Conditions: Hypogonadism
Diabetes

Interventions: Drug: 0.9% saline
Drug: Testosterone

First Posted Date: 2006-07-07

Last Posted Date: 2010-03-30

Lead Sponsor: Barnsley Hospital

Target Recruit Count: 40

Registration Number: NCT00349362

Locations: 🇬🇧
Barnsley Hospital NHS Foundation Trust, Barnsley, South Yorkshire, United Kingdom

Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men

Phase 1

Completed

Conditions: Aging

Interventions: Drug: Placebo
Drug: Testosterone
Drug: Anastrazole
Drug: Dutasteride

First Posted Date: 2006-04-03

Last Posted Date: 2012-07-31

Lead Sponsor: Mayo Clinic

Target Recruit Count: 80

Registration Number: NCT00309855

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Does Testosterone Improve Function in Hypogonadal Older Men

Phase 4

Withdrawn

Conditions: Hypogonadism

First Posted Date: 2006-03-17

Last Posted Date: 2015-02-13

Lead Sponsor: North Florida Foundation for Research and Education

Registration Number: NCT00304213

Locations: 🇺🇸
Nf/Sg Vhs, Gainesville, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy